Clinical Trial Details
| Trial ID: | L5121 |
| Source ID: | NCT01030679 |
| Associated Drug: | Ckd-501 0.5mg |
| Title: | Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: CKD-501 0.5mg|DRUG: CKD-501 1mg|DRUG: CKD-501 2mg|DRUG: Placebo |
| Outcome Measures: | Primary: Change from baseline in fasting plasma glucose at 8 weeks, 8 weeks | Secondary: Change from baseline in Glycemic parameters after 8 weeks, 8 weeks|Change from baseline in Lipid parameters after 8 weeks, 8 weeks|Adverse event profile after 8 weeks of treatment, 8 weeks |
| Sponsor/Collaborators: | Sponsor: Chong Kun Dang Pharmaceutical |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 214 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2007-07 |
| Completion Date: | 2008-10 |
| Results First Posted: | |
| Last Update Posted: | 2009-12-16 |
| Locations: | The Inje University Medical Center, Busan, Korea, Republic of|The Yeungnam University Hospital, Daegu, Korea, Republic of|The Chtholic University of Korea Uijeongbu St. Mary's Hospital, Gyeonggi-do, Korea, Republic of|The Seoul National Univertisy Bundang Hospital, Gyeonggi-do, Korea, Republic of|The Wonju Christian Hospital, Kangwon-Do, Korea, Republic of|The Inje University Sanggye-Paik Hospital, Seoul, Korea, Republic of|The Korea University Anam Hospital, Seoul, Korea, Republic of|The Samsung Medical Center, Seoul, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT01030679 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|